ASTCT guideline (17-expert panel, GRADE) on BPDCN: allogeneic HCT recommended in CR1 or CR2; autologous HCT suggested for unfit patients without marrow involvement; HCT not recommended after primary induction failure or active relapsed-refractory disease.
Guideline
Kharfan-Dabaja et al. Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy